EF Hutton Acquisition Co. I reissued their buy rating on shares of Agenus (NASDAQ:AGEN – Get Rating) in a report published on Wednesday, Benzinga reports. The firm currently has a $8.30 price target on the biotechnology company’s stock.
Separately, HC Wainwright reiterated a buy rating and issued a $8.00 price target on shares of Agenus in a research note on Tuesday, February 28th. One research analyst has rated the stock with a sell rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Agenus has a consensus rating of Moderate Buy and a consensus target price of $7.10.
Agenus Stock Performance
Shares of NASDAQ AGEN opened at $1.70 on Wednesday. Agenus has a 12 month low of $1.25 and a 12 month high of $3.37. The firm has a fifty day simple moving average of $2.27 and a two-hundred day simple moving average of $2.44.
Hedge Funds Weigh In On Agenus
Agenus, Inc is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H.
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.